These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38995739)

  • 1. A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.
    Grommes C; Nandakumar S; Schaff LR; Gavrilovic I; Kaley TJ; Nolan CP; Stone J; Thomas AA; Tang SS; Wolfe J; Bozza A; Wongchai V; Hyde A; Barrett E; Lynch EA; Madzsar JT; Lin A; Piotrowski AF; Pentsova E; Francis JH; Hatzoglou V; Schultz N; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Clin Cancer Res; 2024 Sep; 30(18):4005-4015. PubMed ID: 38995739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
    Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
    Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
    Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
    Du S; Fu DB; A Bota D; Kong XT
    CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
    Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
    Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
    Alcantara M; Chevrier M; Jardin F; Schmitt A; Houillier C; Oberic L; Chinot O; Morschhauser F; Peyrade F; Houot R; Hoang-Xuan K; Ghesquieres H; Soussain C
    J Hematol Oncol; 2024 Sep; 17(1):86. PubMed ID: 39300447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
    Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
    N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
    Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
    Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
    Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
    Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
    JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
    McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
    Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zanubrutinib plus Cytarabine in Patients with Refractory/Relapsed Primary Central Nervous System Lymphoma.
    Lin Z; Ma J; Ma Y; Li Q; Kang H; Zhang M; Chen B
    Acta Haematol; 2024; 147(5):555-563. PubMed ID: 38408440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.